A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Asciminib (Primary) ; Bosutinib
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 02 Aug 2017 Planned End Date changed from 29 Feb 2024 to 22 Mar 2024.
- 02 Aug 2017 Planned primary completion date changed from 29 Feb 2024 to 22 Mar 2024.
- 02 Aug 2017 Planned initiation date changed from 15 Aug 2017 to 6 Sep 2017.